Ovarian Suppression Can Help Protect Ovarian Function and May Preserve Fertility in Younger Women Being Treated with Chemotherapy
Preserving fertility after chemotherapy is an important issue for many, many younger women diagnosed with early-stage breast cancer. Dr. Matteo Lambertini presented research at the 2017 San Antonio Breast Cancer Symposium showing that ovarian suppression with a gonadotropin-releasing hormone analogue such as Lupron, Trelstar, or Zoladex, can safely protect ovarian function and may help preserve fertility in younger women being treated with chemotherapy for early-stage disease.
Listen to the podcast to hear Dr. Lambertini explain:
why earlier studies on this topic had mixed results
the results of the study
the side effects of gonadotropin-releasing hormone analogues
the strategies he recommends to his younger patients diagnosed with early-stage breast cancer who want to have a child after chemotherapy
Dr. Matteo Lambertini is adjunct professor of medical oncology at the University of Genova - IRCCS Policlinico San Martino Hospital.
— Last updated on June 29, 2022, 2:45 PM
This content made possible by Lilly Oncology.